C. FRANK BENNETT - 02 Feb 2026 Form 4 Insider Report for IONIS PHARMACEUTICALS INC (IONS)

Role: EVP, Chief Scientific Officer
Signature: By: Patrick R. O'Neil, attorney-in-fact For: C. Frank Bennett
Issuer symbol: IONS
Transactions as of: 02 Feb 2026
Net transactions value: -$3,558,685
Form type: 4
Filing time: 04 Feb 2026, 16:06:04 UTC
Previous filing: 02 Feb 2026
Next filing: 03 Mar 2026
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
BENNETT C FRANK	EVP, Chief Scientific Officer	2855 GAZELLE COURT, CARLSBAD	By: Patrick R. O'Neil, attorney-in-fact For: C. Frank Bennett	04 Feb 2026	0001073387

This filing has been restated, see here for the amended filing

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	IONS	Common Stock	Sale	$1,651,980	-20,000	-20%	$82.60	80,293	02 Feb 2026	Direct	F1
transaction	IONS	Common Stock	Options Exercise	$2,960,837	+48,626	+61%	$60.89	128,919	02 Feb 2026	Direct
transaction	IONS	Common Stock	Sale	$4,037,339	-48,626	-38%	$83.03	80,293	02 Feb 2026	Direct	F2
transaction	IONS	Common Stock	Options Exercise	$536,694	+16,463	+21%	$32.60	96,756	02 Feb 2026	Direct
transaction	IONS	Common Stock	Sale	$1,366,897	-16,463	-17%	$83.03	80,293	02 Feb 2026	Direct	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	IONS	Non-Qualified Stock Option (right to buy)	Options Exercise	$0	-16,463	-87%	$0.000000	2,406	02 Feb 2026	Common Stock	16,463	$32.60	Direct
transaction	IONS	Non-Qualified Stock Option (right to buy)	Options Exercise	$0	-48,626	-100%	$0.000000	0	02 Feb 2026	Common Stock	48,626	$60.89	Direct

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id	Content
F1	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $81.92 to $82.775 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4.
F2	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $82.775 to $83.34 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) on this Form 4.

Content

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $81.92 to $82.775 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $82.775 to $83.34 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) on this Form 4.